Protect the peptide from direct light, heat, and humidity during handling
Potential drug interactions Sermorelin has no known major drug interactions, but may have the following interactions with certain drugs: Glucocorticoids (prednisone) May blunt growth hormone (GH) release Oral estrogens May increase IGF-1 resistance Insulin or sulfonylureas May alter glycemic control Somatostatin analogs May antagonize Sermorelins effects Dopamine antagonists May disrupt human growth hormone (HGH) regulation GABAergic meds May reduce pulsatility of HGH release Beta blockers (Metoprolol or Propranolol) Other secretagogues/peptides May result in unsafe levels of HGH Other important safety information Sermorelin is only for patients who are at least 30 years old
The investigational vaccine is based on pre-clinical research led by the late Vincent Tuohy, Ph.D., who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic
2003 Jun;13(6):5617
It stimulates angiogenesis via the VEGF-eNOS-NO pathway, accelerates fibroblast migration, and promotes type I collagen synthesis
By activating the mTORC1 signaling pathway, leucine significantly augments MPS, particularly when synergistically administered with resistance training, thereby aiding in the mitigation of age-related anabolic resistance
